[A17-22] Reslizumab (asthma) - Addendum to Commission A17-02
Last updated 06.07.2017
Project no.:
A17-22
Commission:
Commission awarded on 22.05.2017 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Airways and respiratory system
Indication:
Severe eosinophilic asthma
Result of dossier assessment:
Additional study data unsuitable for the derivation of an added benefit; still no added benefit proven
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A17-02 | Reslizumab (severe eosinophilic asthma) – Benefit assessment according to § 35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2017-07-06 A G-BA decision was published.